GSK stock price: EU nod for Nucala in COPD puts the focus on Monday trade
GSK shares closed Friday up 0.8% at 2,198 pence after the EU approved expanded use of Nucala for adults with uncontrolled COPD. Chairman Jonathan Symonds bought 2,500 shares earlier in the week. The stock is up 17% over the past week and nearly 49% in 12 months. GSK trades ex-dividend on Feb. 19.